Brokerages expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report earnings per share (EPS) of $0.06 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Amphastar Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.04 and the highest estimate coming in at $0.09. Amphastar Pharmaceuticals reported earnings of $0.14 per share in the same quarter last year, which would indicate a negative year over year growth rate of 57.1%. The company is expected to issue its next quarterly earnings report on Monday, August 14th.

According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full year earnings of $0.25 per share for the current fiscal year, with EPS estimates ranging from $0.16 to $0.34. For the next year, analysts forecast that the business will report earnings of $0.75 per share, with EPS estimates ranging from $0.49 to $1.00. Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, May 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by $0.03. Amphastar Pharmaceuticals had a return on equity of 2.69% and a net margin of 3.54%. The company had revenue of $56.67 million for the quarter, compared to the consensus estimate of $63.74 million. During the same period in the prior year, the company earned $0.12 EPS. The firm’s revenue was down 4.5% compared to the same quarter last year.

AMPH has been the topic of a number of recent analyst reports. Jefferies Group LLC set a $21.00 target price on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, April 20th. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Finally, TheStreet upgraded Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $20.14.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/19/amphastar-pharmaceuticals-inc-nasdaqamph-expected-to-announce-earnings-of-0-06-per-share.html.

In other news, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $17.07, for a total transaction of $170,700.00. Following the sale, the director now directly owns 28,844 shares in the company, valued at $492,367.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard K. Prins sold 7,500 shares of the business’s stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $15.43, for a total value of $115,725.00. Following the sale, the director now owns 30,500 shares in the company, valued at $470,615. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,982 shares of company stock worth $735,850. Company insiders own 11.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue boosted its stake in Amphastar Pharmaceuticals by 77.2% in the second quarter. State of Alaska Department of Revenue now owns 7,052 shares of the company’s stock valued at $125,000 after buying an additional 3,072 shares during the period. Fisher Asset Management LLC boosted its stake in Amphastar Pharmaceuticals by 29.5% in the second quarter. Fisher Asset Management LLC now owns 195,547 shares of the company’s stock valued at $3,492,000 after buying an additional 44,492 shares during the period. Bank of Montreal Can boosted its stake in Amphastar Pharmaceuticals by 1,032.9% in the second quarter. Bank of Montreal Can now owns 69,649 shares of the company’s stock valued at $1,244,000 after buying an additional 63,501 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its stake in Amphastar Pharmaceuticals by 24.3% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 216,600 shares of the company’s stock valued at $3,141,000 after buying an additional 42,400 shares during the period. Finally, Tudor Investment Corp ET AL boosted its stake in Amphastar Pharmaceuticals by 33.9% in the first quarter. Tudor Investment Corp ET AL now owns 35,387 shares of the company’s stock valued at $513,000 after buying an additional 8,960 shares during the period. Institutional investors own 45.32% of the company’s stock.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down 0.73% during midday trading on Wednesday, reaching $17.74. 180,391 shares of the company’s stock were exchanged. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $21.75. The company’s 50 day moving average is $17.35 and its 200-day moving average is $15.96. The stock has a market cap of $811.37 million, a PE ratio of 93.37 and a beta of 1.68.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.